Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 701–800 of 873
Typ-2-Diabetes: Efpeglenatid verbessert kardiovaskuläre und renale Outcomes
Lichert, F. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1647-6556
Overview of the 81st Scientific Sessions of the American Diabetes Association
Day, C. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.331
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Agarwalla, A., Gruen, J., Peters, C. J., Sinnenberg, L. E., OWENS, A. T., & Reza, N. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.31
Diabetes Medications and Cardiovascular Disease Prevention
Rho, J.-S., Lee, Y.-A., Song, S.-W., & Kang, S. G. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.2.61
GLP-1-Rezeptoragonisten und Modulation des kardiovaskulären Risikos
Marx, N. (2022) · CardioVasc · doi:10.1007/s15027-022-3670-1
Herz und Diabetes: Welche Bedeutung haben GLP-1-Rezeptor-Agonisten in der Kardiologie?
Moellmann, J., & Lehrke, M. (2022) · Herz · doi:10.1007/s00059-022-05130-w
Müller‐Wieland, D., & Marx, N. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_12-1
Ferreira, J. P., & Neves, J. S. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2694
Rico-Fontalvo, J. E., Hernández, J. D. M., Daza-Arnedo, R., & Cabrales, J. (2022) · Revista Colombiana de Nefrología · doi:10.22265/acnef.9.3.602
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115349
Novel Drugs for Kidney Diseases Treatment
Meneses, G. C., Santos, R. S. D. S., Martins, A. M. C., & Daher, E. D. F. (2022) · Springer eBooks · doi:10.1007/978-3-031-11570-7_8
Morales-Villegas, E. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3207 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control
La Salle, J., Uusinarkaus, K., Family Medicine, C. P. C., Marso, S. P., Cardiovascular Medicine, H. M. H., & Pantalone, K. M. (2023) · Journal of Family Medicine · doi:10.26420/jfammed.2023.1325
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
New obesity drug therapies – what is the added value?
Keller, U. B. (2022) · doi:10.36000/hbt.2022.07.002
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · doi:10.2337/figshare.22186279.v1
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · doi:10.2337/figshare.22186279
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_35
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-2
Demidova, T. Y., Titova, V. V., & Izmaylova, M. Y. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202425
¿Qué nos han demostrado los arGLP-1 en el abordaje integral temprano?
García, M. C. G., & Lachica, L. Á. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.manejointegral.art3
Ghnaimat, M. A., Al-Samen, M. A. A., Hijleh, M. O. A., Jarrah, N. S., Al-Momani, M., Barghouthi, H., Khawaldeh, A., Khoury, T., Said, R. A., & Matalka, M. S. (2023) · Journal of Family Medicine and Health Care · doi:10.11648/j.jfmhc.20230903.13
Müller‐Wieland, D., & Marx, N. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_12
Particularités des complications microangiopathiques du diabète chez le sujet âgé
Buysschaert, M., Boureau, A., Dhane, Y., & Bauduceau, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(23)00297-3
How to Use Type 2 Diabetes Treatments in Clinical Practice
Karagiannis, T., Liakos, A., & Τσάπας, Α. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch37
Pandey, A., Patel, K. V., & Verma, S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch50
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Dual GIP and GLP-1 agonists and changes in the lipid spectrum
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.006
Cellular and molecular mechanisms of the antidiabetic drugs under clinical trials
Eerike, M., Nagireddy, U. M., & Ravi, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00017-x
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438489
Marx, N., Müller‐Wieland, D., Espinola–Klein, C., Halle, M., Birkenhagen, A., Diemert, P., Mahfoud, F., Wienbergen, H., & Schütt, K. S. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00689-6
COVID-19 and diabetes: health risks
Sokolova, E., Palamarenko, M. A., Osipov, A. A., Chaulin, A. M., Eliseeva, E., & Koryakin, E. S. (2024) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2024-102-3-252-256
Janota, O., Kwiendacz, H., Olejarz, A., Włosowicz, A., Pabis, P., Gumprecht, J., Alam, U., Lip, G. Y. H., & Nabrdalik, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2392017
Arzneitherapie des Diabetes mellitus Typ 2 – ist Metformin neuerdings verzichtbar?
Gallwitz, B. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01755-7
Agonistes des récepteurs du GLP-1 : impact sur la maladie rénale diabétique
Wéra, M., & Paquot, N. (2024) · JMIG · doi:10.53738/revmed.2024.20.884.1488
Interpretation of cardiovascular outcome trials results of new antidiabetic agents
Koh, G., & CHIN, H. (2024) · Journal of Medicine and Life Science · doi:10.22730/jmls.2024.21.3.62
Neue Medikamente zur Behandlung von Nierenerkrankungen
Meneses, G. C., Santos, R. S. D. S., Martins, A. M. C., & Daher, E. D. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65236-3_8
Schulze-Bauer, H., Staudacher, M., Steiner, S., & Schlager, O. (2024) · Herz · doi:10.1007/s00059-024-05286-7
Management kardiovaskulärer Erkrankungen bei Patienten mit Diabetes: Die Kernpunkte der Leitlinien
Marx, N., Müller‐Wieland, D., Espinola–Klein, C., Halle, M., Birkenhagen, A., Diemert, P., Mahfoud, F., Wienbergen, H., & Schütt, K. S. (2025) · CME · doi:10.1007/s11298-024-4125-z
Impact of GLP-1 Receptor Agonists on Body Weight and Cardiovascular Outcomes: A Systematic Review
Mutairi, A. A. (2025) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v24i10.79201
Evaluating risks and benefits of Newer Diabetes medications when Used in Routine care (ENDURe)Preprint
Colacci, M., Hurst, M., Fritz, J. L., Olar, P., Ray, P., Verma, A. A., Razak, F. A., Mamdani, M., Quinn, K. L., Rosella, L. C., et al. (2025) · medRxiv · doi:10.1101/2025.02.20.25322631
Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
chen, X., Guan, J., Dai, H., Gao, Y., you, X., wang, T., & Wang, G. A. (2025) · Research Square · doi:10.21203/rs.3.rs-5036735/v1
chen, X., Guan, J., Dai, H., Gao, Y., you, X., wang, T., & Wang, G. A. (2025) · Research Square · doi:10.21203/rs.3.rs-5036735/v2
Branch, K. R., Lam, C. S. P., Islam, S., Prato, S. D., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., & Gerstein, H. C. (2025) · Diabetes Care · doi:10.2337/dc24-2629
Self-citationAddressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide
Kumar, R., Singh, S. K., Singh, S., & Kumar, A. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20251843
Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management
Zargar, A. H., Balagopalan, J. P., Bhattacharyya, A., Almeida, A. F., Taraphder, A., Bansal, S., Dani, S., Deka, N., Jain, S., & Swami, O. C. (2025) · Cureus · doi:10.7759/cureus.88561
Ilany, J., Cohen, O., & Gorfine, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6863965/v1
Antiplatelet treatment in different clinical settings
Agewall, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf060
Prajapati, P., Shafi, N., Pachchipulusu, V., Fatima, N., Noorien, S., Biswas, S. K., Narula, A., Aishwarya, K., Prajapati, S. D., Patel, M. K., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334855
Perencin, A., Ceolin, C., Papa, M. V., Marzio, B. D., Zanforlini, B. M., Devita, M., Curreri, C., GASPARINI, G., Sergi, G., & RUI, M. D. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09709-5
Educational Case: Diabetic nephropathy
Gripp, E. W., & Chan, J. S. Y. (2025) · Academic Pathology · doi:10.1016/j.acpath.2025.100218
Soto, E. A. M., Gómez-Luján, M., Espinal, J. E. V., Fajardo, I. A. A., Mariscal, H., García, M. N. E., López, E. T., & Echeona, K. A. (2025) · SAGA Revista Científica Multidisciplinar · doi:10.63415/saga.v2i3.257
Soto, E. A. M., Araujo, J. E. G., Quezada, J. U. C., Carlos, I. O. M., Luna, P., Florez, Á. H. S., López, E. T., & Ortega, A. S. F. (2025) · IECCMEXICO · doi:10.64784/008
Yuan, D., Vangaveti, V., Arojojoye, O. A., & Malabu, U. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/2663671
Rai, A., Kolli, M., Singh, G. P., Rishu, R., Cai, C. Y. L., Balaji, H., Pongen, B., Joy, S., & Shahid Sai, A. K. (2025) · Cureus · doi:10.7759/cureus.96162
Ghosal, S., & Ghosal, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01817-5
Digital Technology in the Management and Prevention of Diabetes, volume II
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7053-1
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Albumin-based drug/gene delivery systems
Zhang, W., Men, J., Zhou, J., & Yu, G. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0243
Exploring Endothelial Injury Syndromes: Mechanisms, Markers, and Therapeutic Potential
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7154-5
Müller‐Wieland, D., & Marx, N. (2024) · Springer eBooks · doi:10.1007/978-3-662-69938-6_12
Kammer, M., Heinzel, A., Hu, K., Meiselbach, H., Gregorich, M., Busch, M., Duffin, K. L., Gomez, M. F., Eckardt, K., & Oberbauer, R. (2024) · Figshare · doi:10.6084/m9.figshare.26578994
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.24987936
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferović, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438492
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2024) · Figshare · doi:10.6084/m9.figshare.26575994
Santos‐Pardo, I., Witt, N., Angerås, O., & Nyström, T. (2023) · Figshare · doi:10.6084/m9.figshare.24779232
Husain, M., Consoli, A., Remigis, A. D., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Figshare · doi:10.6084/m9.figshare.19682255
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Figshare · doi:10.6084/m9.figshare.23597476
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Figshare · doi:10.6084/m9.figshare.16696428
Longato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Figshare · doi:10.6084/m9.figshare.17007077
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.24987804
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26606593
Avdic, T., Carlsen, H. K., Rawshani, A., Gudbjörnsdottir, S., Mandalenakis, Z., & Eliasson, B. (2024) · Figshare · doi:10.6084/m9.figshare.26707071
Андреевна, К. Е., Анатольевна, Г. А., Егоровна, С. Е., & Tukish, O. V. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-4-7-15
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Muzammil, M., & Riyaz, M. (2025) · Telangana journal of IMA. · doi:10.4103/tjima.tjima_31_25
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
GLP-1 Receptor Agonists and Cardiovascular Effects: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsarafcc6e977
Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis
Park, B. (2025) · TSpace (University of Toronto)
Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
Sattar, N. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00013-6
Self-citationPrevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future
Everett, B. M., Pagidipati, N. J., & Wang, C. C. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00011-2
Marx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Diabetic kidney disease: mechanisms of development, diagnostic methods and treatment
Skvortsov, V. V., Skvortsova, E. M., Suvorkov, S. R., & Saraev, S. S. (2026) · Therapist’s Bulletin · doi:10.31550/2712-8601-vt-2026-1-5
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Raveendra, K., Joseph, T., Kang, J., Hurdus, B., Cutting, U., Haris, M., Younsi, T., Aslam, A., Petrie, M. C., Metra, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag091
The Cardiovascular Continuum Between Hypertension, Diabetes and Cardiovascular Disease
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7717-2
Wang, H., Zhang, L., Shi, B., Li, H., Liu, Y., & Zhu, L. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02148-6
Abomohsen, M., Rifai, M. K., Gadelmawla, A. F., Alghzawi, H. M., Elgendy, M. S., Bakr, H. M., Friedman, A., & Idries, I. Y. M. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.04.001
Aiwuyo, H. O., Obiebi, I. P., Atoe-Imagbe, O. M., Okhuaihesuyi, U., Osarenkhoe, J. O., Kweki, A. G., Iruolagbe, C. O., Oboirien, I. O., Akinti, O., Okakpu, E. C., et al. (2026) · Cureus · doi:10.7759/cureus.107195
Yau, K. Y. T. (2025) · TSpace (University of Toronto)
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review
Bihelek, N., Burke, S., & Barry, A. R. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag121
Cardiac GLP1R gene expression: A cross-species single-cell transcriptomic analysis
Dostal, C., Ernst, M., Reiner, J., Snelling, R., Hu, C., Pokreisz, P., Kiss, A., & Podesser, B. K. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00113
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
Chuang, S., Liu, S.-C., Chien, K., Lin, C. Y., Tsai, M.-C., & Shih, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70915
Matsushita, T., Wada, Y., Saburi, M., Kobayashi, K., Tsukamoto, S., Kawanami, D., Suzuki, D., Tsuriya, D., Wakui, H., Kanasaki, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02695-5
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
